's-Gravenhage

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Ended recruitment
  2022-502779-40-00 5 2023-09-04 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended recruitment
  2022-501608-85-00 5 2023-05-09 Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
• HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended recruitment
  2022-501939-16-00 5 2023-05-09 Heart failure (HF) with mildly reduced ejection fraction (HFmrEF) or H
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended recruitment
  2022-502664-21-00 6 2023-05-01 multiple sclerosis
• Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti … Ended recruitment
  2022-501534-33-00 6 2023-03-06 Unexplained Subfertility, infertility
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Ended recruitment
  2023-504996-26-00 5 2022-07-21 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat … Ended recruitment
  2024-514965-20-00 4 2022-06-02 Breast cancer
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter
• LEGACY Ended recruitment
  2023-504360-42-00 6 2022-05-13 Non-ST-segment elevation acute coronary syndrome
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Personalized dosing of ocrelizumab in MS Ended recruitment
  2024-513193-22-00 11 2022-03-16 Multiple Sclerosis
• Phase 3 Study of Belzutifan in Combination With Lenvatinib Versus Cabozantinib for Treatment of RCC Ended recruitment
  2024-510620-39-00 5 2021-04-19 Advanced RCC with clear cell component
• A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refracto … Ended recruitment
  2023-503916-33-00 5 2021-03-24 Diffuse Large B-Cell Lymphoma (DLBCL)
• An open study for participants who have been on darolutamide treatment in any other Bayer study Ended recruitment
  2022-502084-38-00 5 2020-10-16 Cancer
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal … Ended recruitment
  2024-513422-38-00 5 2020-09-28 Newly diagnosed multiple myeloma
• Capivasertib + Abiraterone as Treatment for Patients with Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency (CAP … Ended recruitment
  2023-504998-20-00 5 2020-09-18 Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN def
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Study Comparing Zanubrutinib (BGB-3111) plus Rituximab Versus Bendamustine plus Rituximab in Patients with Previously Untreated Mantle Cell … Ended recruitment
  2023-509908-15-00 10 2020-01-20 Mantle Cell Lymphoma
• A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit … Ended recruitment
  2023-503829-18-00 4 2019-12-05 Acute myeloid leukemia
• Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu … Ended recruitment
  2023-505321-14-00 10 2019-09-06 Warm Autoimmune Hemolytic Anemia
• Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended recruitment
  2024-516205-23-00 4 2019-04-09 Breast cancer

Showing 97–120 of 149 trials